Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'POOR METABOLIZERS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 192 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Dojo, M; Azuma, T; Saito, T; Ohtani, M; Muramatsu, A; Kuriyama, M
      Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pyloriinfection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

      DIGESTIVE AND LIVER DISEASE
    2. Gerson, LB; Triadafilopoulos, G
      Proton pump inhibitors and their drug interactions: an evidence-based approach

      EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
    3. Yamada, S; Onda, M; Kato, S; Matsuda, N; Matsuhisa, T; Yamada, N; Miki, M; Matsukura, N
      Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations

      JOURNAL OF GASTROENTEROLOGY
    4. Davis, MP; Homsi, J
      The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine

      SUPPORTIVE CARE IN CANCER
    5. Yasui-Furukori, N; Kondo, T; Suzuki, A; Mihara, K; Tokinaga, N; Inoue, Y; Otani, K; Kaneko, S
      Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol

      SCHIZOPHRENIA RESEARCH
    6. Harhangi, BS; Oostra, BA; Heutink, P; van Duijn, CM; Hofman, A; Breteler, MMB
      CYP2D6 polymorphism in Parkinson's disease: The Rotterdam study

      MOVEMENT DISORDERS
    7. Sakai, T; Aoyama, N; Kita, T; Sakaeda, T; Nishiguchi, K; Nishitora, Y; Hohda, T; Sirasaka, D; Tamura, T; Tanigawara, Y; Kasuga, M; Okumura, K
      CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

      PHARMACEUTICAL RESEARCH
    8. Kita, T; Tanigawara, Y; Aoyama, N; Hohda, T; Saijoh, Y; Komada, F; Sakaeda, T; Okumura, K; Sakai, T; Kasuga, M
      CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability

      PHARMACEUTICAL RESEARCH
    9. Roh, HK; Chung, JY; Oh, DY; Park, CS; Svensson, JO; Dahl, ML; Bertilsson, L
      Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    10. Enggaard, TP; Poulsen, L; Arendt-Nielsen, L; Hansen, SH; Bjornsdottir, I; Gram, LF; Sindrup, SH
      The analgesic effect of codeine as compared to imipramine in different human experimental pain models

      PAIN
    11. Eap, CB; Broly, F; Mino, A; Hammig, R; Deglon, JJ; Uehlinger, C; Meili, D; Chevalley, AF; Bertschy, G; Zullino, D; Kosel, M; Preisig, M; Baumann, P
      Cytochrome P450 2D6 genotype and methadone steady-state concentrations

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    12. Kosuge, K; Jun, Y; Watanabe, H; Kimura, M; Nishimoto, M; Ishizaki, T; Ohashi, K
      Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamicsof diazepam in relation to CYP2C19 genotype status

      DRUG METABOLISM AND DISPOSITION
    13. Furuta, S; Kamada, E; Suzuki, T; Sugimoto, T; Kawabata, Y; Shinozaki, Y; Sano, H
      Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole

      XENOBIOTICA
    14. Bergmann, TK; Bathum, L; Brosen, K
      Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    15. Laine, K; Tybring, G; Hartter, S; Andersson, K; Svensson, JO; Widen, J; Bertilsson, L
      Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    16. Williams, DG; Hatch, DJ; Howard, RF
      Codeine phosphate in paediatric medicine

      BRITISH JOURNAL OF ANAESTHESIA
    17. Ariyoshi, N; Sawamura, Y; Kamataki, T
      A novel single nucleotide polymorphism altering stability and activity of CYP2A6

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    18. Luginbuhl, M; Schnider, TW; Petersen-Felix, S; Arendt-Nielsen, L; Zbinden, AM
      Comparison of five experimental pain tests to measure analgesic effects ofalfentanil

      ANESTHESIOLOGY
    19. Meisel, C; Roots, I; Cascorbi, I; Brinkmann, U; Brockmoller, J
      How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    20. Stefanovic, M; Topic, E; Ivanisevic, AM; Relja, M; Korsic, M
      Genotyping of CYP2D6 in Parkinson's disease

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    21. Vree, TB; Van Dongen, RTM; Koopman-Kimenai, PM
      Codeine analgesia is due to codeine-6-glucuronide, not morphine

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    22. Roberts, R; Sullivan, P; Joyce, P; Kennedy, MA
      Rapid and comprehensive determination of cytochrome P450CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction

      HUMAN MUTATION
    23. Flockhart, DA; Oesterheld, JR
      Cytochrome P450-mediated drug interactions

      CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA
    24. Isaza, CA; Henao, J; Lopez, AM; Cacabelos, R
      Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population

      METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    25. Wilcox, RA; Owen, H
      Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: Implications for the Australian anaesthetist

      ANAESTHESIA AND INTENSIVE CARE
    26. Somer, M; Kallio, J; Pesonen, U; Pyykko, K; Huupponen, R; Scheinin, M
      Influence of hydroxychloroquine on the bioavailability of oral metoprolol

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    27. Dalen, P; Dahl, ML; Andersson, K; Bertilsson, L
      Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    28. Kathiramalainathan, K; Kaplan, HL; Romach, MK; Busto, UE; Li, NY; Sawe, J; Tyndale, RF; Sellers, EM
      Inhibition of cytochrome P450 2D6 modifies codeine abuse liability

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    29. Chou, WH; Yan, FX; de Leon, J; Barnhill, J; Rogers, T; Cronin, M; Pho, M; Xiao, V; Ryder, TB; Liu, WW; Teiling, C; Wedlund, PJ
      Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    30. Egan, LJ; Murray, JA
      New perspectives in gastric acid suppression: Genetic polymorphisms predict the efficacy of proton pump inhibitors

      DIGESTIVE DISEASES
    31. Shimoda, K; Morita, S; Yokono, A; Someya, T; Hirokane, G; Sunahara, N; Takahashi, S
      CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients

      THERAPEUTIC DRUG MONITORING
    32. Mihara, K; Suzuki, A; Kondo, T; Yasui, N; Furukori, H; Nagashima, U; Ono, S; Kaneko, S; Otani, K; Inoue, Y
      Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

      THERAPEUTIC DRUG MONITORING
    33. Veefkind, AH; Hafmans, PMJ; Hoencamp, E
      Venlafaxine serum levels and CYP2D6 genotype

      THERAPEUTIC DRUG MONITORING
    34. Scordo, MG; Spina, E; Romeo, P; Dahl, ML; Bertilsson, L; Johansson, I; Sjoqvist, F
      CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    35. Fukuda, T; Nishida, Y; Zhou, Q; Yamamoto, I; Kondo, S; Azuma, J
      The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    36. Herrlin, K; Massele, AY; Rimoy, G; Alm, C; Rais, M; Ericsson, O; Bertilsson, L; Gustafsson, LL
      Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    37. Hersberger, M; Marti-Jaun, J; Rentsch, K; Hanseler, E
      Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR

      CLINICAL CHEMISTRY
    38. Someya, T; Suzuki, Y; Shimoda, K; Hirokane, G; Morita, S; Yokono, A; Inoue, Y; Takahashi, S
      The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    39. Weber, WW
      Populations and genetic polymorphisms

      MOLECULAR DIAGNOSIS
    40. Lessard, E; Hamelin, BA; Labbe, L; O'Hara, G; Belanger, PM; Turgeon, J
      Involvement of CYP2D6 activity in the N-oxidation of procainamide in man

      PHARMACOGENETICS
    41. Bernal, ML; Sinues, B; Johansson, I; McLellan, RA; Wennerholm, A; Dahl, ML; Ingelman-Sundberg, M; Bertilsson, L
      Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine

      PHARMACOGENETICS
    42. Jorge, LF; Eichelbaum, M; Griese, EU; Inaba, T; Arias, TD
      Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations

      PHARMACOGENETICS
    43. Kondo, T; Suzuki, A; Mihara, K; Yasui, N; Kaneko, S
      CYP2D6 genotype and plasma levels of haloperidol and reduced haloperidol in Japanese

      MOLECULAR MEDICINE: NOVEL FINDINGS OF GENE DIAGNOSIS, REGULATION OF GENE EXPRESSION, AND GENE THERAPY
    44. Druid, H; Holmgren, P; Carlsson, B; Ahlner, J
      Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results

      FORENSIC SCIENCE INTERNATIONAL
    45. Ammon, S; Hofmann, U; Griese, EU; Gugeler, N; Mikus, G
      Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    46. Coller, JK; Somogyi, AA; Bochner, F
      Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    47. Coutts, RT; Urichuk, LJ
      Polymorphic cytochromes P450 and drugs used in psychiatry

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    48. Greenblatt, DJ; von Moltke, LL; Hermatz, JS; Shader, RI
      Human cytochromes mediating sertraline biotransformation: Seeking attribution

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    49. Yasui, N; Kondo, T; Otani, K; Furukori, H; Mihara, K; Suzuki, A; Kaneko, S; Inoue, Y
      Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    50. Alfaro, CL; Lam, YWF; Simpson, J; Ereshefsky, L
      CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    51. Lew, EA
      Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    52. Chen, SQ; Wedlund, PJ
      Correlation between cytochrome P-450CYP2D6 CYP2D6) genotype and phenotype

      ACTA PHARMACOLOGICA SINICA
    53. Kovacs, P; Edwards, DJ; Lalka, D; Scheiwe, WM; Stoeckel, K
      High-dose omeprazole: Use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping

      THERAPEUTIC DRUG MONITORING
    54. Bannwarth, B
      Risk-benefit assessment of opioids in chronic noncancer pain

      DRUG SAFETY
    55. Evans, WE; Relling, MV
      Pharmacogenomics: Translating functional genomics into rational therapeutics

      SCIENCE
    56. Kortunay, S; Bozkurt, A; Bathum, L; Basci, NE; Calguneri, M; Brosen, K; Kayaalp, SO
      CYP2D6 polymorphism in systemic lupus erythematosus patients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    57. Mihara, K; Suzuki, A; Kondo, T; Yasui, N; Furukori, H; Nagashima, U; Otani, K; Kaneko, S; Inoue, Y
      Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    58. Rusin, M; Butkiewicz, D; Malusecka, E; Zborek, A; Harasim, J; Czyzewski, K; Bennett, WP; Shields, PG; Weston, A; Welsh, JA; Krzyzowska-Gruca, S; Chorazy, M; Harris, CC
      Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland

      BRITISH JOURNAL OF CANCER
    59. Yasumori, T; Chen, LS; Li, QH; Ueda, M; Tsuzuki, T; Goldstein, JA; Kato, R; Yamazoe, Y
      Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: Difference in chiral preference of CYP2C9 and CYP2C19

      BIOCHEMICAL PHARMACOLOGY
    60. Ingelman-Sundberg, M; Oscarson, M; McLellan, RA
      Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

      TRENDS IN PHARMACOLOGICAL SCIENCES
    61. Scordo, MG; Spina, E; Facciola, G; Avenoso, A; Johansson, I; Dahl, ML
      Cytochrome P450 2D6 genotype and steady state plasma levels of risperidoneand 9-hydroxyrisperidone

      PSYCHOPHARMACOLOGY
    62. SHAH RR; MIDGLEY JM; BRANCH SK
      STEREOCHEMICAL ORIGIN OF SOME CLINICALLY SIGNIFICANT DRUG SAFETY CONCERNS - LESSONS FOR FUTURE DRUG DEVELOPMENT

      Adverse drug reactions and toxicological reviews
    63. DROLL K; BRUCEMENSAH K; OTTON SV; GAEDIGK A; SELLERS EM; TYNDALE RF
      COMPARISON OF 3 CYP2D6 PROBE SUBSTRATES AND GENOTYPE IN GHANAIANS, CHINESE AND CAUCASIANS

      Pharmacogenetics
    64. PANG CP; ZHANG J; WOO J; CHAN D; LAW LK; TONG SF; KWOK T; KAY R
      RARITY OF DEBRISOQUINE HYDROXYLASE GENE POLYMORPHISM IN CHINESE PATIENTS WITH PARKINSONS-DISEASE

      Movement disorders
    65. YOKOI T; KAMATAKI T
      GENETIC-POLYMORPHISM OF DRUG-METABOLIZING-ENZYMES - NEW MUTATIONS IN CYP2D6 AND CYP2A6 GENES IN JAPANESE

      Pharmaceutical research
    66. CACCIA S
      METABOLISM OF THE NEWER ANTIDEPRESSANTS - AN OVERVIEW OF THE PHARMACOLOGICAL AND PHARMACOKINETIC IMPLICATIONS

      Clinical pharmacokinetics
    67. JEFFERSON JW
      DRUG AND DIET INTERACTIONS - AVOIDING THERAPEUTIC PARALYSIS

      The Journal of clinical psychiatry
    68. GREENBLATT DJ; VONMOLTKE LL; HARMATZ JS; SHADER RI
      DRUG-INTERACTIONS WITH NEWER ANTIDEPRESSANTS - ROLE OF HUMAN CYTOCHROMES P450

      The Journal of clinical psychiatry
    69. BAKER GB; FANG J; SINHA S; COUTTS RT
      METABOLIC-DRUG INTERACTIONS WITH SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) ANTIDEPRESSANTS

      Neuroscience and biobehavioral reviews
    70. SAGAR M; SEENSALU R; TYBRING G; DAHL ML; BERTILSSON L
      CYP2C19 GENOTYPE AND PHENOTYPE DETERMINED WITH OMEPRAZOLE IN PATIENTSWITH ACID-RELATED DISORDERS WITH AND WITHOUT HELICOBACTER-PYLORI INFECTION

      Scandinavian journal of gastroenterology
    71. POULSEN L; RIISHEDE L; BROSEN K; CLEMENSEN S; SINDRUP SH
      CODEINE IN POSTOPERATIVE PAIN - STUDY OF THE INFLUENCE OF SPARTEINE PHENOTYPE AND SERUM CONCENTRATIONS OF MORPHINE AND MORPHINE-6-GLUCURONIDE

      European Journal of Clinical Pharmacology
    72. NORMANN C; HESSLINGER B; BAUER J; BERGER M; WALDEN J
      THE ROLE OF THE HEPATIC CYTOCHROME-P450 ENZYMES IN PSYCHOPHARMACOLOGY

      Nervenarzt
    73. Heiskanen, T; Olkkola, KT; Kalso, E
      Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics ofoxycodone

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    74. STEIJNS LSW; VANDERWEIDE J
      ULTRARAPID DRUG-METABOLISM - PCR-BASED DETECTION OF CYP2D6 GENE DUPLICATION

      Clinical chemistry
    75. SUZUKI A; OTANI K; MIHARA K; YASUI N; KONDO T; TOKINAGA N; FURUKORI H; KANEKO S; INOUE Y; HAYASHI K
      EFFECTS OF VARIOUS FACTORS INCLUDING THE CYP2D6 GENOTYPE AND COADMINISTRATION OF FLUNITRAZEPAM ON THE STEADY-STATE PLASMA-CONCENTRATIONS OFBROMPERIDOL AND ITS REDUCED METABOLITE

      Psychopharmacology
    76. ELZEIN R; ZWISCHENBERGER JB; WOOD TG; ABDELRAHMAN SZ; BREKELBAUM C; AU WW
      COMBINED GENETIC-POLYMORPHISM AND RISK FOR DEVELOPMENT OF LUNG-CANCER

      Mutation research. Fundamental and molecular mechanisms of mutagenesis
    77. YASUI N; TYBRING G; OTANI K; MIHARA K; SUZUKI A; SVENSSON JO; KANEKO S
      EFFECTS OF THIORIDAZINE, AN INHIBITOR OF CYP2D6, ON THE STEADY-STATE PLASMA-CONCENTRATIONS OF THE ENANTIOMERS OF MIANSERIN AND ITS ACTIVE METABOLITE, DESMETHYLMIANSERIN, IN DEPRESSED JAPANESE PATIENTS

      Pharmacogenetics
    78. SUZUKI A; OTANI K; MIHARA K; YASUI N; KANEKO S; INOUE Y; HAYASHI K
      EFFECTS OF THE CYP2D6 GENOTYPE ON THE STEADY-STATE PLASMA-CONCENTRATIONS OF HALOPERIDOL AND REDUCED HALOPERIDOL IN JAPANESE SCHIZOPHRENIC-PATIENTS

      Pharmacogenetics
    79. MCLELLAN RA; OSCARSON M; SEIDEGARD J; EVANS DAP; INGELMANSUNDBERG M
      FREQUENT OCCURRENCE OF CYP2D6 GENE DUPLICATION IN SAUDI-ARABIANS

      Pharmacogenetics
    80. OTANI K; YASUI N; KANEKO S; OHKUBO T; OSANAI T; SUGAWARA K; HAYASHI K; CHIBA K; ISHIZAKI T
      EFFECTS OF GENETICALLY-DETERMINED S-MEPHENYTOIN 4-HYDROXYLATION STATUS AND CIGARETTE-SMOKING ON THE SINGLE-DOSE PHARMACOKINETICS OF ORAL ALPRAZOLAM

      Neuropsychopharmacology
    81. MEYER UA; ZANGER UM
      MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG-METABOLISM

      Annual review of pharmacology and toxicology
    82. MASIMIREMBWA CM; HASLER JA
      GENETIC-POLYMORPHISM OF DRUG-METABOLIZING-ENZYMES IN AFRICAN POPULATIONS - IMPLICATIONS FOR THE USE OF NEUROLEPTICS AND ANTIDEPRESSANTS

      Brain research bulletin
    83. RENDIC S; DICARLO FJ
      HUMAN CYTOCHROME-P450 ENZYMES - A STATUS-REPORT SUMMARIZING THEIR REACTIONS, SUBSTRATES, INDUCERS, AND INHIBITORS

      Drug metabolism reviews
    84. ABDELRAHMAN SZ; ANWAR WA; ABDELAAL WE; GHONEIM MA; AU WW
      THE CYP2D6 EXTENSIVE METABOLIZER GENOTYPE IS ASSOCIATED WITH INCREASED RISK FOR BLADDER-CANCER

      Cancer letters
    85. MIHARA K; OTANI K; TYBRING G; DAHL ML; BERTILSSON L; KANEKO S
      THE CYP2D6 GENOTYPE AND PLASMA-CONCENTRATIONS OF MIANSERIN ENANTIOMERS IN RELATION TO THERAPEUTIC RESPONSE TO MIANSERIN IN DEPRESSED JAPANESE PATIENTS

      Journal of clinical psychopharmacology
    86. SPROULE BA; OTTON SV; CHEUNG SW; ZHONG XH; ROMACH MK; SELLERS EM
      CYP2D6 INHIBITION IN PATIENTS TREATED WITH SERTRALINE

      Journal of clinical psychopharmacology
    87. SHAW GL; WEIFFENBACH B; FALK RT; FRAME JN; ISSAQ HJ; MOIR DT; CAPORASO N
      FREQUENCY OF THE VARIANT ALLELE CYP2D6(C) AMONG NORTH-AMERICAN CAUCASIAN LUNG-CANCER PATIENTS AND CONTROLS

      Lung cancer
    88. WEST WL; KNIGHT EM; PRADHAN S; HINDS TS
      INTERPATIENT VARIABILITY - GENETIC PREDISPOSITION AND OTHER GENETIC-FACTORS

      Journal of clinical pharmacology
    89. OLDHAM HG; CLARKE SE
      IN-VITRO IDENTIFICATION OF THE HUMAN CYTOCHROME-P450 ENZYMES INVOLVEDIN THE METABOLISM OF R(-CARVEDILOL AND S(-)-CARVEDILOL())

      Drug metabolism and disposition
    90. KAPLAN HL; BUSTO UE; BAYLON GJ; CHEUNG SW; OTTON SV; SOMER G; SELLERS EM
      INHIBITION OF CYTOCHROME-P450 2D6 METABOLISM OF HYDROCODONE TO HYDROMORPHONE DOES NOT IMPORTANTLY AFFECT ABUSE LIABILITY

      The Journal of pharmacology and experimental therapeutics
    91. FUNCKBRENTANO C; BECQUEMONT L; LENEVEU A; ROUX A; JAILLON P; BEAUNE P
      INHIBITION BY OMEPRAZOLE OF PROGUANIL METABOLISM - MECHANISM OF THE INTERACTION IN-VITRO AND PREDICTION OF IN-VIVO RESULTS FROM THE IN-VITRO EXPERIMENTS

      The Journal of pharmacology and experimental therapeutics
    92. WADELIUS M; DARJ E; FRENNE G; RANE A
      INDUCTION OF CYP2D6 IN PREGNANCY

      Clinical pharmacology and therapeutics
    93. TYBRING G; BOTTIGER Y; WIDEN J; BERTILSSON L
      ENANTIOSELECTIVE HYDROXYLATION OF OMEPRAZOLE CATALYZED BY CYP2C19 IN SWEDISH WHITE SUBJECTS

      Clinical pharmacology and therapeutics
    94. BERTILSSON L; DAHL ML; TYBRING G
      PHARMACOGENETICS OF ANTIDEPRESSANTS - CLINICAL ASPECTS

      Acta psychiatrica Scandinavica
    95. MIHARA K; OTANI K; SUZUKI A; YASUI N; NAKANO H; MENG XM; OHKUBO T; NAGASAKI T; KANEKO S; TSUCHIDA S; SUGAWARA K; GONZALEZ FJ
      RELATIONSHIP BETWEEN THE CYP2D6 GENOTYPE AND THE STEADY-STATE PLASMA-CONCENTRATIONS OF TRAZODONE AND ITS ACTIVE METABOLITE M-CHLOROPHENYLPIPERAZINE

      Psychopharmacology
    96. HUFSCHMID E; THEURILLAT R; WILDERSMITH CH; THORMANN W
      CHARACTERIZATION OF THE GENETIC-POLYMORPHISM OF DIHYDROCODEINE O-DEMETHYLATION IN MAN VIA ANALYSIS OF URINARY DIHYDROCODEINE AND DIHYDROMORPHINE BY MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY

      Journal of chromatography B. Biomedical applications
    97. BERTILSSON L; DAHL ML
      POLYMORPHIC DRUG OXIDATION - RELEVANCE TO THE TREATMENT OF PSYCHIATRIC-DISORDERS

      CNS DRUGS
    98. STUBBINS MJ; HARRIES LW; SMITH G; TARBIT MH; WOLF CR
      GENETIC-ANALYSIS OF THE HUMAN CYTOCHROME-P450 CYP2C9 LOCUS

      Pharmacogenetics
    99. ROH HK; DAHL ML; JOHANSSON I; INGELMANSUNDBERG M; CHA YN; BERTILSSON L
      DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION PHENOTYPES AND GENOTYPESIN A KOREAN POPULATION

      Pharmacogenetics
    100. JOHANSSON I; LUNDQVIST E; DAHL ML; INGELMANSUNDBERG M
      PCR-BASED GENOTYPING FOR DUPLICATED AND DELETED CYP2D6 GENES

      Pharmacogenetics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 11:46:15